Earnings Releases

Guardant Health, Inc. reported full year 2024 results: revenue $675 to $685 million. Guidance raised.

“Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023”

Guardant Health, Inc. reported the quarter ended March 31, 2024 results: revenue $168.5 million, net income $115.0 million, EPS $0.94.

“Revenue was $168.5 million for the first quarter of 2024, a 31% increase from $128.7 million for the corresponding prior year period.”

Victory Capital Holdings, Inc. reported the three months ended March 31, 2024 results: net income GAAP net income of $0.84 per diluted share, EPS GAAP net income of $0.84 per diluted share.

“On May 9, 2024, Victory Capital Holdings, Inc., (the “Company”) issued a press release (the “Earnings Press Release”) reporting results for the three months ended March 31, 2024.”

AH Realty Trust, Inc. reported three months ended March 31, 2024 results: net income $14.8 million, EPS $0.17 per diluted share. Guidance reaffirmed.

“Net income attributable to common stockholders and OP Unit holders of $14.8 million, or $0.17 per diluted share, compared to $2.4 million, or $0.03 per diluted share, for the three months ended March 31, 2023.”

Keenova Therapeutics plc reported the first quarter ended March 29, 2024 results: revenue $467.8 million, net income net loss of $65.4 million. Guidance reaffirmed.

“in such a filing. --- EX-99.1 (EX-99.1) --- Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance Achieves First Quarter Net Sales of $467.8 Million, Reflecting 10.2% Year-Over-Year Growth on a Reported and Constant Currency Basis Reports Net Loss of $65.4 Million , Reflecting a 73.8% Year-Over-Year Improvement; Delivers”

INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: net income Net loss was $4.6 million.

“On May 9, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2024.”

Clearway Energy, Inc. reported the quarter ended March 31, 2024 results: net income Net Loss of $(46) million. Guidance reaffirmed.

“Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) today reported first quarter 2024 financial results, including Net Loss of $(46) million, Adjusted EBITDA of $211 million, Cash from Operating Activities of $81 million, and Cash Available for Distribution (CAFD) of $52 million.”

VYNE Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $0.1 million, net income $6.2 million, EPS $0.15.

“financial statements included in VYNE’s Quarterly Report on Form 10-Q filed today for additional discussion on liquidity and capital resources. Revenues. Revenues totaled $0.1 million for each of the three months ended March 31, 2024 and 2023, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed”

Allakos Inc. updated its the first quarter ended March 31, 2024 guidance (reaffirmed).

“On May 9, 2024, Allakos Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2024.”

TELA Bio, Inc. reported first quarter ended March 31, 2024 results: revenue $16.6 million, net income $5.7 million. Guidance raised.

“Revenue was $16.6 million in the first quarter of 2024, an increase of 39% compared to the same period in 2023. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $11.3 million in the first quarter of 2024, or 68% of revenue, compared to $7.9 million, or 66% of revenue, in the same period in 2023. The increase in gross margin was primarily due to a lower charge for excess and obsolete inventory as a percentage of revenue due to improvements in inventory management. Operating expenses were $23.7 million in the first quarter of 2024, compared to $19.2 million in the same period in 2023. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, con”

Natural Grocers by Vitamin Cottage, Inc. updated its fiscal 2024 guidance (raised).

“Based upon the strength of our results through the second quarter, we are raising our fiscal 2024 outlook for daily average comparable store sales growth and diluted earnings per share.”

Natural Grocers by Vitamin Cottage, Inc. reported three and six months ended March 31, 2024 results: revenue Net sales increased 8.8% to $308.1 million, net income Net income was $8.0 million, EPS diluted earnings per share of $0.35. Guidance raised.

“Natural Grocers by Vitamin Cottage Announces Second Quarter Fiscal 2024 Results Raises Fiscal 2024 Outlook Lakewood, Colorado, May 9, 2024. Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) today announced results for its second quarter of fiscal 2024 ended March 31, 2024. Highlights for Second Quarter Fiscal 2024 Compared to Second Quarter Fiscal 2023 ● Net sales increased 8.8% to $308.1 million; ● Daily average comparable store sales increased 7.5%, and increased 10.2% on a two-year basis; ● Net income was $8.0 million, with diluted earnings per share of $0.35; ● Adjusted EBITDA was $19.7 million; and ● Opened one new store.”

TILE SHOP HOLDINGS, INC. reported first quarter ended March 31, 2024 results: revenue $ 91,728, net income $ 1,689, EPS $ 0.04.

“Three Months Ended (unaudited, dollars in thousands, except per March 31, share data) 2024 2023 Net sales $ 91,728 $ 102,019 Net sales decline (1) (10.1 )% (0.4 )% Comparable store sales (decline) growth (2) (10.2 )% 0.1 % Gross margin rate 65.8 % 64.2 % Income from operations as a % of net sales 2.5 % 4.0 % Net income $ 1,689 $ 2,512 Net income per diluted share $ 0.04 $ 0.06 Adjusted EBITDA $ 7,417 $ 10,313 Adjusted EBITDA as a % of net sales 8.1 % 10.1 % Number of stores open at the end of period 142 142”

Progyny, Inc. reported the three-month period ended March 31, 2024 results: revenue $278,078, net income $16,898, EPS $0.17.

“of February,” said Mark Livingston, Progyny’s Chief Financial Officer. First Quarter 2024 Highlights: (unaudited; in thousands, except per share amounts) 1Q 2024 1Q 2023 Revenue $278,078 $258,394 Gross Profit $62,406 $58,640 Gross Margin 22.4% 22.7% Net Income $16,898 $17,678 Net Income per Diluted Share 1 $0.17 $0.18 Adjusted Earnings Per Diluted Share 2 $0.39”

Lument Finance Trust, Inc. reported the quarter ended March 31, 2024 results: net income GAAP net income attributable to common shareholders for the first quarter was $5.8 million, or $0.11 per share of common, EPS $0.11 per share of common stock.

“On May 9, 2024, Lument Finance Trust, Inc. (the “Company”) issued a press release (the “Release”) and supplemental financial information announcing its financial results for the quarter ended March 31, 2024.”

CrossAmerica Partners LP reported quarter ended March 31, 2024 results: net income Net Loss of $17.5 million.

“Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023”

Tempest Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $7.9 million, EPS $0.36.

“Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.”

Clearside Biomedical, Inc. reported first quarter ended March 31, 2024 results: revenue $230,000, net income $11.8 million, EPS $0.17 per share of common stock.

“by delivering drug directly to the back of the eye via the SCS Microinjector. First Quarter 2024 Financial Results • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023. • Research and development expenses for the first quarter of 2024 were $5.6 million, compared to $4.5 million for the first”

TECOGEN INC. reported three months ended March 31, 2024 results: revenue $6.2 million, net income $1.1 million net loss, EPS $(0.04)/share.

“Tecogen Inc. (OTCQX:TGEN), a leading manufacturer of clean energy products, reported revenues of $6.2 million and net loss of $1.1 million for the quarter ended March 31, 2024 compared to revenues of $5.4 million, and a net loss of $1.5 million in 2023.”

Oportun Financial Corp updated its first quarter ended March 31, 2024 guidance (raised).

“On May 9, 2024, Oportun Financial Corporation (the “Company”) issued a press release regarding the Company’s financial results for its fiscal quarter ended March 31, 2024.”

Tecnoglass Inc. reported the first quarter ended March 31, 2024 results: revenue $192.6 million, net income $29.7 million, or $0.63 per diluted share, EPS $0.63 per diluted share.

“Tecnoglass Reports First Quarter 2024 Results - Revenue of $192.6 Million - - Net Income of $29.7 Million, or $0.63 Per Diluted Share”

CION Investment Corp reported the first quarter ended March 31, 2024 results: revenue $73.6 million, net income $ 6,445, EPS $0.12 per share.

“outstanding 53,960,698 54,292,065 Distributions declared per share $ 0.34 $ 0.54 Total investment income for the three months ended March 31, 2024 and December 31, 2023 was $73.6 million and $60.0 million, respectively. The increase in total investment income was primarily driven by additional investment income from origination and restructuring activities and”

Ready Capital Corp reported first quarter 2024 results: EPS -$(0.45) GAAP loss per share from continuing operations; distributable earnings per share $0.29.

“READY CAPITAL CORPORATION REPORTS FIRST QUARTER 2024 RESULTS - GAAP LOSS PER COMMON SHARE FROM CONTINUING OPERATIONS OF $(0.45) - - DISTRIBUTABLE EARNINGS PER COMMON SHARE OF $0.29 - - DISTRIBUTABLE RETURN ON AVERAGE STOCKHOLDERS’ EQUITY OF 8.6%”

Phio Pharmaceuticals Corp. reported the three months ended March 31, 2024 results: net income Net loss was $2.2 million for the three months ended March 31, 2024.

“On May 9, 2024, Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended March 31, 2024.”

Ares Commercial Real Estate Corp reported the quarter ended March 31, 2024 results: net income $(12.3) million, EPS $(0.23) per diluted common share.

“the registrant issued a press release announcing its financial results for the quarter ended March 31, 2024”

CHUY'S HOLDINGS, INC. reported quarter ended March 31, 2024 results: revenue $110.5 million, net income $6.9 million, EPS $0.40 per diluted share.

“Chuy’s Holdings, Inc. (NASDAQ:CHUY) (the "Company") today announced financial results for the first quarter ended March 31, 2024. Highlights for the first quarter ended March 31, 2024 were as follows : • Revenue was $110.5 million compared to $112.5 million in the first quarter of 2023.”

Acutus Medical, Inc. reported the quarter ended March 31, 2024 results: revenue $3.6 million, net income $2.1 million, EPS $0.07.

“Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024. Recent Highlights: • First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year. • Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the”

Vistance Networks, Inc. reported financial results for first quarter of 2024.

“On May 9, 2024, CommScope Holding Company, Inc. (the “Company” or “CommScope”) issued a press release relating to its financial results for the first quarter of 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1.”

Akebia Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $32.6 million, net income Net loss was $18.0 million. Guidance reaffirmed.

“Total revenues were $32.6 million for the first quarter of 2024 compared to $40.0 million for the first quarter of 2023.”

Coherus Oncology, Inc. reported the quarter ended March 31, 2024 results: revenue $77.1 million, net income $102.9 million, EPS $0.83 per share on a diluted basis.

“reference in such a filing. --- EX-99.1 (EX-99.1) --- ​ ​ ​ Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update ​ – Net revenue of $77.1 million in Q1 2024 – ​ – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – ​ – New debt and royalty financing replaces $75 million term loan, with debt”

MARA Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $165.2 million, net income $337.2 million, EPS $1.26 per diluted share.

“such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Marathon Digital Holdings Reports First Quarter 2024 Results – Revenues Increase 223% to a Record $165.2 Million – Net Income Increases 184% to a Record $337.2 Million, or $1.26 per Diluted Share – Adjusted EBITDA Increases 266% to a Record $528.8 Million Fort Lauderdale, FL – May 9, 2024 –”

Regulus Therapeutics Inc. reported the first quarter ended March 31, 2024 results: net income $8.5 million, or $0.29 per share (basic and diluted), EPS $0.29 per share (basic and diluted).

“Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.”

Warby Parker Inc. reported the first quarter ended March 31, 2024 results: revenue $200.0 million, net income GAAP net loss of $2.7 million. Guidance raised.

“• Net revenue increased $28.0 million, or 16.3%, to $200.0 million, as compared to the prior year period. • GAAP net loss of $2.7 million.”

Aura Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.

“Aura Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”

OptiNose, Inc. reported three-month period ended March 31, 2024 results: revenue approximately $14.9 million in net revenue from sales of XHANCE, net income a net loss of approximately $14.1 million.

“For the three-month period ended March 31, 2024, the Company expects to report: • approximately $14.9 million in net revenue from sales of XHANCE; • approximately $21.7 of operating expenses, consisting of approximately $1.2 million of research and development expenses and approximately $20.5 million of selling, general and administrative expenses; • a loss from operations of approximately $8.1 million; and • a net loss of approximately $14.1 million.”

Adverum Biotechnologies, Inc. reported the quarter ended March 31, 2024 results: net income Net Loss was $24.8 million, or $1.50 per basic and diluted share, EPS $1.50 per basic and diluted share.

“Net Loss was $24.8 million, or $1.50 per basic and diluted share, for the three months ended March 31, 2024, compared to $29.1 million, or $2.90 per basic and diluted share for the same period in 2023.”

Townsquare Media, Inc. reported the first quarter ended March 31, 2024 results: revenue $99.6 million, EPS $0.06. Guidance reaffirmed.

“$27.0 million. For the full year 2024, net revenue guidance is reaffirmed to be between $440 million and $460 million, and Adjusted EBITDA guidance is reaffirmed to be between $100 million and $110 million. Quarter Ended March 31, 2024 Compared to the Quarter Ended March 31, 2023 Net Revenue Net revenue for the three months ended March 31, 2024 decreased $3.5”

Sensus Healthcare, Inc. reported the three months ended March 31, 2024 results: revenue $10.7 million, net income $2.3 million, or $0.14 per diluted share, EPS $0.14 per diluted share.

“Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold · Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter”

CarGurus, Inc. reported the first quarter ended March 31, 2024 results: revenue $215.8 million, net income $21.3 million.

“On May 9, 2024, CarGurus, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024.”

Groupon, Inc. reported the first quarter ended March 31, 2024 results: revenue $123.1 million, net income $11.5 million.

“Reports consolidated revenue growth for the first time since 2016 Excluding Goods category, North America segment revenues grew 8% compared to prior year • Global revenu e of $123.1 million • Global billings of $381.1 million • Net loss of $11.5 million • Adjusted EBITDA of $19.5 million • Exited Q1 with $158.7 million in cash CHICAGO - May 9, 2024 - Groupon, Inc.”

Revance Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

“Total net revenue for the first quarter ended March 31, 2024 was $51.9 million compared to $45.8 million for the same period last year, representing an increase of 13%, due to an increase in DAXXIFY sales volume.”

Carisma Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.

“On May 9, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”

Sweetgreen, Inc. reported Fiscal year 2024 results: revenue $660 million to $675 million. Guidance raised.

“For fiscal year 2024, we are updating our financial guidance to reflect the strength of the first quarter. • 23-27 Net New Restaurant Openings • Revenue ranging from $660 million to $675 million • Same-Store Sales Change between 4-6% • Restaurant-Level Profit Margin of 18.5%-20% • Adjusted EBITDA between $10 million to $19 million”

Sweetgreen, Inc. reported First quarter ended March 31, 2024 results: revenue $157.9 million, net income $(26.1) million.

“ended March 31, 2024. First quarter 2024 financial highlights For the first quarter of fiscal year 2024, compared to the first quarter of fiscal year 2023: • Total revenue was $157.9 million, versus $125.1 million in the prior year period, an increase of 26%. • Same-Store Sales Change of 5% was consistent with the prior year period. • AUV of $2.9 million was”

Nutex Health Inc. reported first quarter 2024 results: revenue $67.5 million, net income Net loss attributable to Nutex Health Inc. of $0.4 million.

“Total revenue of $67.5 million as compared to total revenue of $56.3 million for the three months ended March 31, 2023, an increase of approximately 20%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 6.7% in 2024 compared to 2023. ● Total visits from the Hospital Division were 40,068 for the first quarter 2024 as compared to 33,085 for the first quarter 2023, an increase of 6,983 or 21.1%. Of this visit growth, mature hospitals increased by 5.3% in 2024 compared to 2023. ● Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $5.1 million for the three months ended March 31, 2023.”

Expensify, Inc. reported the quarter ended March 31, 2024 results: revenue $33.5 million, net income Net loss was $3.8 million. Guidance raised.

“wait to show you on the earnings call (or visit exfy.com/roadmap to see it yourself)! -david Founder and CEO of Expensify First Quarter 2024 Highlights Financial: • Revenue was $33.5 million, a decrease of 16% compared to the same period last year. • Generated $3.5 million cash from operating activities. • Free cash flow was $5.2 million. • Net loss was $3.8 million,”

BGSF, INC. reported first fiscal quarter ended March 31, 2024 results: revenue $68.8 million, net income ($0.8) million, or ($0.07) per diluted share.

“and professional workforce solutions, today reported financial results for the first fiscal quarter ended March 31, 2024. Q1 2024 Highlights from Operations: • Revenues were $68.8 million for 2024, compared to $75.3 million for 2023. • Gross profit was $23.4 million, from $26.8 million in 2023. • Operating income was $0.4 million in 2024, up from an operating loss”

Arcadia Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024.

“On May 9, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2024.”

Alarm.com Holdings, Inc. reported full year 2024 results: revenue total revenue expected in the range of $914.5 million to $931.0 million, net income non-GAAP adjusted net income attributable to common stockholders expected in the range of $118.5 million to $119.5 milli, EPS non-GAAP adjusted net income attributable to common stockholders expected to be $2.14 to $2.16 per diluted share. Guidance raised.

“For the full year 2024: • SaaS and license revenue is expected to be in the range of $624.5 million to $625.0 million. • Total revenue is expected to be in the range of $914.5 million to $931.0 million, which includes anticipated hardware and other revenue in the range of $290.0 million to $306.0 million. • Non-GAAP adjusted EBITDA is expected to be in the range of $164.0 million to $166.0 million. • Non-GAAP adjusted net income attributable to common stockholders is expected to be in the range of $118.5 million to $119.5 million, based on an estimated tax rate of 21.0%. • Based on an expected 55.3 million weighted average diluted shares outstanding, non-GAAP adjusted net income attributable to common stockholders is expected to be $2.14 to $2.16 per diluted share.”

Alarm.com Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $223.3 million, net income $23.6 million, EPS $0.44 per diluted share.

“First Quarter 2024 Financial Results as Compared to First Quarter 2023 • SaaS and license revenue increased 11.0% to $150.3 million, compared to $135.4 million. • Total revenue increased 6.5% to $223.3 million, compared to $209.7 million. • GAAP net income attributable to common stockholders increased 63.7% to $23.6 million, or $0.44 per diluted share, compared to $14.4 million, or $0.28 per diluted share.”